Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $56.38.

A number of research analysts have recently weighed in on the company. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Morgan Stanley set a $43.00 target price on shares of Immunocore in a research note on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a report on Monday, July 13th.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its position in shares of Immunocore by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company’s stock valued at $1,534,000 after purchasing an additional 1,197 shares during the period. GAMMA Investing LLC lifted its stake in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after buying an additional 1,286 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in Immunocore in the 4th quarter worth $47,000. Royal Bank of Canada boosted its holdings in Immunocore by 5.2% in the 1st quarter. Royal Bank of Canada now owns 44,714 shares of the company’s stock worth $1,348,000 after buying an additional 2,228 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in Immunocore by 24.2% in the 1st quarter. Public Employees Retirement System of Ohio now owns 31,253 shares of the company’s stock worth $942,000 after buying an additional 6,090 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Stock Performance

NASDAQ:IMCR traded down $0.08 during mid-day trading on Friday, hitting $29.40. 924,922 shares of the company traded hands, compared to its average volume of 456,921. The stock’s fifty day moving average price is $33.09 and its 200-day moving average price is $31.62. Immunocore has a one year low of $27.50 and a one year high of $40.71. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -79.46 and a beta of 0.81.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Research analysts anticipate that Immunocore will post 0.06 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapies designed to treat cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and redirect the patient’s T cells to destroy those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is a bispecific TCR therapy approved in the United States and Europe for certain adults with unresectable or metastatic uveal melanoma, a rare form of eye cancer.